GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » ROE % Adjusted to Book Value

Tengion (Tengion) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2014)


View and export this data going back to 2010. Start your Free Trial

What is Tengion ROE % Adjusted to Book Value?

Tengion's ROE % for the quarter that ended in Sep. 2014 was 0.00%. Tengion's PB Ratio for the quarter that ended in Sep. 2014 was N/A. Tengion's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2014 was N/A.

Tengion ROE % Adjusted to Book Value Historical Data

The historical data trend for Tengion's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion ROE % Adjusted to Book Value Chart

Tengion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - -106.35 - -

Tengion Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Equity - - -

Competitive Comparison of Tengion's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Tengion's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tengion's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tengion's ROE % Adjusted to Book Value falls into.


Tengion ROE % Adjusted to Book Value Calculation

Tengion's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2013 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Tengion's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2014 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tengion ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Tengion's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Tengion (Tengion) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
VITIF HSTC NTRR TLOG NSPX ERGO OPLI GLAG FPMI ADYNF ENTB CAPS BTHE GOVX LCAR CTBO IMUC GNBT ICOTF TIKRF
Traded in Other Exchanges
N/A
Address
3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Website
http://www.tengion.com
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Executives
John L Miclot director, officer: President and CEO 5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis officer: Chf. Fin. Offr, VP Fin. C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc 10 percent owner 710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach officer: VP and Chief Commercial Offcr C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger director, officer: President and CEO C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P 10 percent owner 901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-20-2010